Phase 3 readouts by year
Late-stage studies grouped by the year of their estimated primary completion date, the sponsor's own estimate of when the last participant is assessed for the primary endpoint. Every phase, filterable, is on the readout calendar.
| Year | Studies | Drugs |
|---|---|---|
| Readouts expected in 2026 | 202 | 164 |
| Readouts expected in 2027 | 839 | 503 |
| Readouts expected in 2028 | 721 | 453 |
| Readouts expected in 2029 | 434 | 331 |
| Readouts expected in 2030 | 266 | 218 |